First lupus breakthrough in 50 years

First lupus breakthrough in 50 years
Professor Fabienne Mackay, Head of the Department of Immunology at Monash University

(Medical Xpress) -- A Monash researcher has played a crucial role in the first major lupus treatment breakthrough for over 50 years.

Professor Fabienne Mackay Head of the Department of at Monash University, discovered a new factor in the development of the disease, something known as BAFF - B cell Activating Factor.

It has led directly to the development of a medication called Benlysta, which was approved by the US Food and Drug Authority for release last month.

Professor Mackay explains that B make for invaders such as and other foreign bodies, like pollen.

“BAFF helps B cells survive, which is a good thing. But if there is too much BAFF, then there can be an overproduction of B cells and they hang about for longer than they should - in particular that are normally meant to die because they are harmful. Autoimmunity will be initiated, and this is how the immune system ends up attacking the body’s own cells,” Professor Mackay said.

Lupus is an autoimmune inflammatory disease affecting about five million people worldwide. An autoimmune problem is one where the body’s immune system attacks the body itself.  In the case of lupus, the attacks connective tissue in the joints, lungs, kidneys and heart, causing joint and skin diseases in most patients, and organ and blood disorders in about half of lupus sufferers.

Professor Mackay was the first to show that the overproduction of BAFF was driving lupus. In a follow up study, elevated levels of BAFF were discovered in patients with a number of autoimmune diseases including lupus, rheumatoid arthritis and Sjögren’s syndrome.

She said this was an exciting discovery as it implied that if BAFF production can be blocked, the entire cascade effect that resulted in autoimmune disease could be prevented.

Manufacturers of the drug, GlaxoSmithKline designed their clinical trials in line with the insights from Professor Mackay’s experimental data.

Professor Mackay says that one of the reasons for her interest in lupus is its affect on the Indigenous Australian population. Aboriginal Australians suffers from at a rate double that of the non-Aboriginal population.

“I am very pleased to have created the platform of knowledge from which effective therapies can springboard. In particular, I have long been concerned about the higher incidence of this disease and associated morbidity within Indigenous Australians populations and the limited arsenal of therapies, many very toxic, and it is wonderful news that a medication has been developed which may be able to help them.”

Provided by Monash University
Citation: First lupus breakthrough in 50 years (2011, April 28) retrieved 21 August 2019 from https://medicalxpress.com/news/2011-04-lupus-breakthrough-years.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

May 01, 2011
"Manufacturers of the drug, GlaxoSmithKline..."

Obvious question: How much does the drug cost, and who owns the intellectual property on it?

If a university researcher developed the knowledge base to produce the drug, how should intellectual property on it be handled? How is it currently arranged?

Those are questions the writer should have looked into, instead of just copying the Monash press release.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more